Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases
December 05, 2016 16:05 ET
|
Achillion Pharmaceuticals, Inc.
SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced novel research into complement biology that both expands the understanding of this...
Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of Hematology
November 03, 2016 09:01 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts have been accepted for poster presentation at the...
Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs
November 03, 2016 09:00 ET
|
Achillion Pharmaceuticals, Inc.
Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016Achillion’s phase I MAD study with oral factor D inhibitor...
Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop
September 06, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of two posters which detailed novel preclinical research into...
Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference
August 09, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Reports Second Quarter 2016 Financial Results
August 04, 2016 16:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second...
Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
June 10, 2016 03:30 ET
|
Achillion Pharmaceuticals, Inc.
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 - - Results support initiation...
Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
May 19, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers - NEW HAVEN,...
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
May 03, 2016 06:05 ET
|
Achillion Pharmaceuticals, Inc.
- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 – ...